The Critical Role of Molecular Profiling in Cholangiocarcinoma

July 15th 2020

Sponsored Content

BiTE Platform and the Evolution Toward Off-The-Shelf Immuno-Oncology Approaches

June 2nd 2020

Amgen Oncology is committed to investigating innovative approaches to fighting cancer, across both hematological malignancies and solid tumors.

ASCO: New data for Alecensa shows 5-year overall survival in ALK-positive NSCLC

May 30th 2020

On Friday 29 May at the ASCO20 Virtual Scientific Programme, Roche presented updated data from the pivotal phase III ALEX clinical study.

Higher-Risk Myelodysplastic Syndromes: Lacking Treatment Advances in Over a Decade

May 4th 2020

Continued research is critical to potentially bring a targeted therapeutic option to patients with higher-risk myelodysplastic syndromes, to improve overall survival, manage symptoms, and preserve quality of life.

ESMO Data Show More Can Be Done for Cancer of Unknown Primary Patients

September 28th 2019

Two research papers presented by Roche and Foundation Medicine at the 2019 European Society of Medical Oncology (ESMO) Annual Meeting demonstrate both the promise of an innovative precision medicine driven clinical trial for patients with cancer of unknown primary, as well as the challenges of identifying eligible patients for the trial, according to ESMO guidelines.

The Importance of Genetic Testing in Ovarian Cancer: Diagnosis and Treatment

June 25th 2019

Angeles Alvarez Secord, MD, MHSc, discusses the importance of genetic testing and tumor testing in ovarian cancer and the potential impact on treatment decisions.

Biosimilars in Cancer Care: Potentially Improving Patient Access to Essential Therapies9,10

June 17th 2019

Gary Fanjiang, MD, vice president of Biosimilars Global Development, Amgen, discusses the development of biosimilars and some of the clinical considerations related to their use.

Seeking Ways to Extend Progression-Free Survival for Patients with Multiple Myeloma

March 5th 2019

New data presented at this year’s American Society of Hematology Annual Meeting showed that adding DARZALEX® (daratumumab) to standard of care multiple myeloma therapies may extend survival and achieve levels of minimal residual disease not previously seen.

YOUR Cancer Movement Spotlights Oncology HCPs and Community

January 13th 2019

Advancing cancer care requires more than just science. It’s a collective effort driven by passionate individuals and organizations dedicated to making a difference for those living with and affected by cancer.

TIL Therapy May Provide Second-Line Option for Cervical Cancer

October 25th 2018

Investigators are optimistic that LN-145, an autologous tumor-infiltrating lymphocyte investigational therapy, could be a potential treatment option for patients with recurrent, metastatic, or persistent cervical cancer.